dermal sheath cells

[Amniox] Amniox Medical, Inc announced the initiation of the first of two planned multi center randomized controlled phase III clinical trials that will be conducted at 20 investigational sites across the U.S with an enrollment of 220 patients in each trial. These trials will study the benefits and risks of using TTAX01 to achieve complete wound closure of complex non-healing diabetic foot ulcers with high-risk factors of ulcer depth indicating exposed bone, tendon, muscle, and/or joint capsule, and clinical suspicion of osteomyelitis.